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Abstract
Background Up-to-date information on human epidermal growth factor receptor 2 (HER2) status in breast cancer (BC) is
important, as expression can vary during the course of the disease, necessitating anti-HER2 therapy adjustments. Repeat biopsies,
however, are not always possible. In this feasibility trial we assessed whether 89Zr-trastuzumab PET could support diagnostic
understanding and aid clinical decision making, when HER2 status could not be determined by standard work up. Additionally,
HER2 status on circulating tumour cells (CTCs) was assessed.
Patients and methods 89Zr-trastuzumab PETwas performed in patients if disease HER2 status remained unclear after standard
work up (bone scan, 18F-FDG PET, CT and if feasible a biopsy). PET result and central pathologic revision of available tumour
biopsies were reported to the referring physician. CTC HER2 status prior to PET was evaluated afterwards and therefore not
reported. Diagnostic understanding and treatment decision questionnaires were completed by the referring physicians before,
directly after and ≥ 3 months after 89Zr-trastuzumab PET.
Results Twenty patients were enrolled: 8 with two primary cancers (HER2-positive and HER2-negative BC or BC and non-BC),
7 with metastases inaccessible for biopsy, 4 with prior HER2-positive and -negative metastases and 1 with primary BC with
equivocal HER2 status. 89Zr-trastuzumab PET was positive in 12 patients, negative in 7 and equivocal in 1 patient. In 15/20
patients, 89Zr-trastuzumab PET supported treatment decision. The scan altered treatment of 8 patients, increased physicians’
confidence without affecting treatment in 10, and improved physicians’ disease understanding in 18 patients. In 10/20 patients
CTCs were detected; 6/10 showed HER2 expression. CTC HER2 status was not correlated to 89Zr-trastuzumab PET result or
treatment decision.
Conclusion 89Zr-trastuzumab PET supports clinical decision making when HER2 status cannot be determined by standard work
up. The impact of CTC HER2 status needs to be further explored.
Keywords 89Zr-trastuzumab PET . Breast cancer . Human epidermal growth factor receptor 2 . Clinical decisionmaking
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Introduction
In metastatic breast cancer, treatment options are largely de-
pendent upon the presence of the oestrogen receptor, proges-
terone receptor and human epidermal growth factor receptor 2
(HER2), in addition to tumour load and location. The outcome
of HER2 positive metastatic disease has fundamentally im-
proved since the development of effective HER2 targeting
agents such as trastuzumab, pertuzumab and trastuzumab-
emtansine [1]. In this light, it is of particular interest that
HER2 status can change during disease course, consequently
necessitating anti-HER2 therapy adjustment. Furthermore,
HER2 status discordancy between primary and residual ormet-
astatic lesions, either HER2 loss or gain [2], was related to
shorter disease-free and overall patient survival in retrospective
[3, 4] and prospective analyses [5]. This discordancy, measured
by immunohistochemistry (IHC) and/or in situ hybridization
(ISH) techniques, ranged between 0 and 33% [2, 3, 6–14].
Moreover, HER2 expression can be heterogeneous within the
same tumour [6, 15, 16]. Therefore, temporal and spatial het-
erogeneity may fundamentally affect HER2 status and there-
fore treatment response. Based on this data, clinical guidelines
encourage repeat biopsies during the course of the disease.
However, due to technical or patient related factors, tumour
lesions are not always (safely) accessible, leaving the clinician
with a dilemma with regard to the disease’s HER2 status.
HER2 imaging using 89Zr-trastuzumab positron emission
tomography (PET) could be a strategy to noninvasively assess
HER2 expression in tumour lesions throughout the whole
body [17, 18]. It might, therefore, become a valuable tool to
guide clinical decision making in metastatic breast cancer pa-
tients, who—despite extensive work-up—pose a clinical di-
lemma [19, 20]. Characterization of circulating tumour cells
(CTCs) might be another patient-friendly method to assess
HER2 status on metastatic cells [21]. Since CTCs are likely
shed from different tumour sites—metastases and the primary
tumour, if still present—they might reflect both HER2 status
and tumour heterogeneity. Consequently, the aim of this clin-
ical feasibility trial was to assess whether 89Zr-trastuzumab
PET supports clinical decision making in patients suspected
of metastatic or locally recurrent HER2-positive breast cancer,
presenting with a dilemma defined as failure of the standard
work-up to evaluate the present HER2 status of their disease.
In addition, HER2 status of CTCs was assessed and correlated
to treatment decision and 89Zr-trastuzumab PET result.
Patients and methods
Patient population
This prospective single-centre clinical trial protocol was ap-
proved by the medical ethics committee of the University
Medical Centre Groningen (UMCG; ClinicalTrials.gov
identifier NCT01832051). All patients provided written
informed consent.
Patients with suspected metastatic disease or local recur-
rence of HER2-positive breast cancer with a clinical dilemma
defined as failure of standard work-up to evaluate the HER2
status were eligible. HER2-positivity, reported in the patient’s
history, was defined positive with an IHC of score 3+ or IHC
of score 2+ followed by ISH showing HER2 amplification
according to the American Society of Clinical Oncology
guidelines [22]. Standard imaging work-up preferably
consisted of a computed tomography (CT) of the chest and
abdomen, a bone scintigraphy and a fluorine-18-
fluorodeoxyglucose (18F-FDG) PET scan, accompanied by a
metastasis biopsy, if feasible. Other eligibility criteria included
age ≥ 18 years and Eastern Cooperative Oncology Group per-
formance status of 0–2. Patients with a history of allergic
reactions to immunoglobulins and pregnant or lactating wom-
en, as well as patients with any inabilities not allowing com-
pliance with the study procedures, were excluded.
89Zr-trastuzumab PET scan
Clinical grade 89Zr-trastuzumab was produced at the UMCG
as described previously [17]. Patients received 37 MBq (±
10%; ~1 m Ci) 89Zr-trastuzumab intravenously supplemented
with unlabeled antibody to a total amount of 50 mg
trastuzumab. Four days postinjection, head to upper thigh
was scanned in up to nine bed positions with 5 min/bed posi-
tion in combination with a low dose CT scan for attenuation
correction and anatomic reference with a Biograph mCT 64-
slice PET/CTcamera (Siemens). PETscans were reconstructed
and visually analysed by one dedicated nuclear medicine phy-
sician. The 89Zr-trastuzumab PET scan was considered posi-
tive, when in comparison to the 18F-FDG PETand in conjunc-
tion with conventional imaging (e.g. contrast enhanced CT
scan, bone scan or MRI in case of brain metastases) the entire
tumour load or a dominant part of the tumour load showed
89Zr-trastuzumab tumour uptake [23]. 89Zr-trastuzumab tu-
mour uptake was considered substantial when tumour tracer
uptake in visceral lesions (excluding brain) was at least com-
parable to or higher than liver background or in case of brain
metastases when 89Zr-trastuzumab uptakewas exceeding brain
background uptake allowing clear identification of the metas-
tasis. Interpretation of 89Zr-trastuzumab uptake in bone lesions
was assessed in relation with visceral metastases.
Retrospectively, PET images were reconstructed using the
harmonized reconstruction algorithm recommended for
multicentre 89Zr-mAb PET scan trials [24] and all tumour
lesions on the conventional imaging were recorded, including
measurability according to RECIST 1.1 [25] and prior radia-
tion therapy. Tumour lesions with a diameter of >15 mm on
contrast enhanced CT scan were quantified, when tumour
Eur J Nucl Med Mol Imaging (2018) 45:2300–2306 2301
tracer uptake was considered not to be influenced by sur-
rounding tissue and when a lesion was not irradiated
≤6 months of the 89Zr-trastuzumab PET scan. With the
AMIDE (A Medical Image Data Examiner) software (version
0.9.3, [26]) radioactivity was quantified in manually drawn
volumes of interest around tumour lesions and several back-
ground organs, and standardized uptake values (SUV) were
calculated. We report SUVmax for tumour lesions and
SUVmean for normal organ tracer uptake.
Clinical value
To assess the influence of the 89Zr-trastuzumab PET scan on
treatment decision, referring physicians completed earlier val-
idated questionnaires before, directly after and > 3 months af-
ter the 89Zr-trastuzumab PET scan [27]. Information on the
patient’s history, which dilemma incited the referral for 89Zr-
trastuzumab PET, as well as the intended treatment were
assessed with the first questionnaire. In the second question-
naire, completed after receiving the scan result, the treating
physician was asked to give the final diagnosis, the chosen
treatment strategy and information on potential additional
tests planned. With the last questionnaire, referring physicians
were asked to rate the contribution of the 89Zr-trastuzumab
PET scan to their diagnostic understanding of the patient’s
disease and the choice of therapy using a 5-point scale
(Supplementary Table S1). All questionnaires were checked
for internal consistency.
Archival tumour samples
Available archival tumour samples from the primary tumour
site(s) or metastases were centrally revised and IHC (SP3;
rabbit monoclonal antibody; NeoMarkers, Lab Vision Corp.,
Thermo Fisher Scientific, Fremont, California, USA), and in
case of an IHC 2+ score ISH (PathVysion HER2/neu DNA
probe kit, Vysis, Abbott Molecular, Des Plaines, IL) were
repeated. HER2 positivity was defined as IHC 3+, or IHC
2+ with a positive ISH (HER2:CEP17 ratio ≥ 2.0 or an aver-
age of ≥6.0 HER2 copies per nucleus; [22]).
Circulating tumour cell analysis
Before tracer injection, blood for CTC enumeration and CTC
HER2 expression analysis was collected. Samples were
transported to the laboratory of Clinical Tumour
Immunology, Erasmus MC Cancer Institute, Rotterdam, the
Netherlands, for analysis. One CellSave tube was used to ob-
tain an EpCAM-based CTC count from 7.5 mL blood using
the Epithelial Cell Kit (Janssen Diagnostics LLC, Raritan, NJ,
USA) on CellSearch System according to the manufacturer’s
instructions. CTCs were further characterized for HER2 ex-
pression within the Cell-Search system by a FITC-labelled
anti-HER2 antibody as described by the manufacturer
(CellSearch tumour phenotyping reagent HER2/neu; Janssen
Diagnostics LLC). HER2 immunofluorescence staining inten-
sity of 3+ and 2+ were scored as HER2-positive as described
earlier [28]. CTCHER2 status was evaluated after inclusion of
all patients and was not reported to the referring physician.
Statistical analysis
Statistical analyses were performed using SPSS Version 23.
To assess relation between CTC result and 89Zr-trastuzumab
scan result or chosen treatment strategy, Spearman’s correla-
tion was used. P ≤ 0.05 was considered to be a significant
difference. Data are presented as mean ± standard deviation
(SD), unless otherwise stated.
Results
Patient characteristics
Twenty patients were enrolled between July 2013 and June
2015 from all over the Netherlands and the Northern border
area of Germany, with a median distance to our centre of
125 km (range 20–247, Table 1). The 89Zr-trastuzumab PET
scan was requested by the referring physicians (all: medical
oncologists) due to following reasons (Supplementary Table
S2): (i) To differentiate between metastases of two primary
cancers, either two primary breast cancers (one HER2-
positive and the other HER2-negative), or a HER2-positive
breast cancer and a second primary cancer from another origin
(N = 8), (ii) to assess HER2 status of a single lesion
Table 1 Patient characteristics
Characteristic All patients (N = 20)
Median age, y (range) 56 (37–71)
Median travel distance to facility with










Reported main clinical dilemma
Two primary cancers 8
Unfeasibility of (repeated) biopsy 7
Heterogeneous HER2 status over time 4
Equivocal histopathological workup 1
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inaccessible for biopsy, or in case of multiple lesions inability
to perform repeat biopsies (N = 7), (iii) to assess HER2 ex-
pression of metastatic breast cancer with known heteroge-
neous HER2 status over time (N = 4), and (iv) to evaluate
HER2 expression in metastatic breast cancer with prior equiv-
ocal histopathological result (HER2 IHC score 2+, ISH result:
average 4.23 HER2 gene copies/nucleus, N = 1).
89Zr-trastuzumab PET
The highest normal organ 89Zr-trastuzumab uptake was ob-
served in the liver, followed by the kidney, intestine (=faeces),
blood pool and the spleen; the lowest was seen in subcutane-
ous tissue and the brain (Supplementary Figure S1).
At visual assessment, 89Zr-trastuzumab tumour uptake was
considered positive in 12 patients, negative in seven patients and
equivocal in one patient (Fig. 1 and Supplementary Table S2).
Retrospectively, a total of 404 tumour lesions were delin-
eated on 89Zr-trastuzumab PET after primary visual assess-
ment of which 264 (65%) were considered evaluable. In two
patients, none of the known metastases appeared on 89Zr-
trastuzumab PET and their scans, therefore, were considered
negative. In the remaining 18 patients a median of 9 lesions
(range 1–69) was evaluable. Heterogeneity of tumour tracer
uptake was observed within patients, with a maximal 8-fold
difference within one patient. Also, tumour tracer uptake var-
ied greatly between patients, with a maximal 13-fold differ-
ence (data not shown).
HER2 status in tumour biopsies in comparison
to 89Zr-trastuzumab PET
For central revision a total of 42 tumour samples of 20 patients
were available (primary N = 18, secondary N = 10, metastasis
N = 14). One patient, who had reported HER2-positive dis-
ease, was diagnosed with heterogeneous disease after central
pathology revision (Table 2). Furthermore, two out of ten
patients with a reported combination of HER2-positive and
HER2-negative disease and the one patient with the equivocal
histopathological result were diagnosed with HER2-negative
disease after central revision.
The 89Zr-trastuzumab PET scan was positive in seven out
of eight patients with a previously HER2 positive primary
tumour, and in five out of nine patients with a previous com-
bination of HER2-positive and HER2-negative disease ac-
cording to available tumour tissue (Table 2).
Clinical value of 89Zr-trastuzumab PET
The work-up including 89Zr-trastuzumab PET scan improved
the treating physician’s understanding of the patient’s disease in
18 (90%) patients (Fig. 2). The confidence over the (unaltered)
treatment choice was improved in ten patients (50%), and in
eight patients (40%) the treatment was changed. Five patients
were started on anti-HER2 treatment and three patients did not
receive HER2-targeting agents as a consequence of the 89Zr-
trastuzumab scan (Table 3). In one patient the scan did not
influence the understanding and/or treatment choice, and one
physician of a patient with osteosarcoma and simultaneous
HER2-positive breast cancer, rated choice of treatment based
on the 89Zr-trastuzumab PET as non-beneficial for the patient,
although the scan improved her understanding of the disease.
CTC HER2 status
CTCs were found in half of the patient population (median
number of CTCs/7.5 mL = 6.5, range 1–99). In six of them,
HER2-positive CTCs were found and three of the six patients
a l so had a pos i t ive 89Zr- t ras tuzumab PET scan
(Supplementary Table S3). Two out of the six patients, both
Fig. 1 18F-FDG (left) and 89Zr-trastuzumab PET scans (right) of three
patients: Example of a patient with a 89Zr-trastuzumab PET scan
considered HER2-positive (a), a 89Zr-trastuzumab PET scan considered
HER2-negative (b) and an 89Zr-trastuzumab PET scan considered equiv-
ocal (c)
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with positive 89Zr-trastuzumab PET, received anti-HER2
treatment subsequently. Overall, CTC result was not correlat-
ed to 89Zr-trastuzumab PET result or subsequent treatment
decision (correlation with PET result: r = 0.074, P = 0.84; cor-
relation with treatment decision: r = −0.37, P = 0.92).
Discussion
In this small prospective clinical feasibility trial we show for
the first time that 89Zr-trastuzumab PET can support
diagnostic understanding and clinical decision making when
HER2 status of metastatic or locally recurrent breast cancer
cannot be determined by standard work up.
The 89Zr-trastuzumab PET scan improved the physician’s
understanding of the patient’s disease in the majority of pa-
tients and the treatment strategy was changed in 40% of the
study population. Five patients received initially unplanned
anti-HER2 therapy, whereas in three patients, intended anti-
HER2 therapy was withheld. By doing this, the latter patients
were possibly saved from toxicity of a potentially ineffective
treatment. Moreover, the savings of treatment-related costs
Table 2 Reported HER2 status in
biopsies of primary tumours and
metastases versus result of central
pathology revision, and 89Zr-
trastuzumab PET result
Patient Reported HER2 status HER2 status after central revision 89Zr-trastuzumab PET result
1 HER2+ and HER2- HER2+ and HER2- Positive
2 HER2+ HER2+ Positive
3 HER2+ and HER2- HER2-a Negative
4 HER2+ and HER2- HER2+ and HER2- Positive
5 HER2+ HER2+ Negativeb
6 HER2+ HER2+ Positive
7 HER2+ and HER2- HER2+ and HER2- Equivocal
8 HER2+ HER2+ Positive
9 HER2+ and HER2- HER2+ and HER2- Negative
10 HER2+ HER2+ Positive
11 HER2+ and HER2- HER2+ and HER2- Positive
12 HER2+ and HER2- HER2+ and HER2- Negative
13 HER2+ and HER2- HER2+ and HER2- Positive
14 HER2+ and HER2- HER2-a Negative
15 HER2+ HER2+ Positive
16 HER2+ HER2+ Positive
17 HER2+ and HER2- HER2+ and HER2- Negative
18 equivocal HER2- Negative
19 HER2+ HER2+ and HER2-a Positive
20 HER2+ HER2+ Positive
a Initial HER2 IHC interpretation of primary tumour biopsy false positive
b Leptomeningeal metastases visualized on MRI where not visible on 89 Zr-trastuzumab PET either due to neg-
ative HER2 status or due to their size below the detection limit
Fig. 2 Contribution of the 89Zr-
trastuzumab PET scan to the
treating physicians diagnostic
understanding (left) and choice of
therapy (right) using a 5-point
scale
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outweigh scan-related costs manifold. Thereby, distance to
89Zr-trastuzumab PET was no issue in our trial as patients
were willing to travel up to almost 250 km (~150 miles), im-
plying that such molecular scan techniques, although local-
ized only in specialized centres, can be within reach of a vast
majority of patients. Using additional molecular imaging in
standard clinical care will increase radiation exposure. In case
of a 89Zr-trastuzumab PET, this additional radiation exposure
equals that of one diagnostic CT scan of the chest, abdomen
and pelvis [29–32]. The balance between risks and benefits of
any additional procedure should always be carefully consid-
ered in any patient population. In this particular population, a
diagnostic dilemma is known to negatively affect their surviv-
al if left unsolved. In light of the potentially helpful informa-
tion gained by the scan and also considering the incurable
nature of their disease, we think that the benefits of a 89Zr-
trastuzumab PET outweigh the risks in this particular patient
population. Therefore, we consider this scan as suitable for
clinical practice.
CTC analysis in metastatic breast cancer has shown to be a
strong prognostic factor [33–36]. Since CTCs probably orig-
inate from different tumour sites, they might also provide a
comprehensive view of tumour characteristics like HER2 sta-
tus, including tumour heterogeneity. In our trial, CTCs were
only detected in half of the patients, which corresponds with
the earlier reported CTC detection rate [36]. The impact of
CTC HER2 status on clinical decision making is unclear from
the present study, as the result was not reported to the referring
physician. Therefore this will have to be further explored.
However, central pathology revision including renewed
HER2 staining, and subsequent comparison of primary tu-
mour and metastases biopsies, did deliver new insights in
HER2 status in three out of 20 patients in this study.
Therefore this could be worth considering in the standard
setting.
Validation of molecular scan techniques is still an ongoing
process. Clinical utility of 89Zr-trastuzumab PET, especially
the relation of scan results with treatment response and sur-
vival data in recently diagnosed metastatic breast cancer pa-
tients, is currently assessed in a prospective, multicentre ob-
servational cohort study conducted in the Netherlands
(ClinicalTrials.gov Identifier: NCT01957332). In this trial,
intra-patient heterogeneity of tumour tracer uptake will also
further be evaluated, as so far the clinical implication of the
observed heterogeneity is unclear. The trial, furthermore, sup-
ports validation and standardization of interpretation of this
PET imaging technique, which is instrumental for potential
further wider application as possible biomarker for treatment
response in the future. Additionally, the impact of CTC enu-
meration and characterization for HER2 and its relation with
89Zr-trastuzumab PET is further explored in the mentioned
trial. However, the present study already establishes 89Zr-
trastuzumab PET as a diagnostic tool to help the treating phy-
sician in clinical decision making, in this niche population of
patients with an otherwise undetermined HER2 status of their
disease.
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